161 related articles for article (PubMed ID: 34708773)
41. Quantitative assessment of macular contraction and vitreoretinal interface alterations in diabetic macular edema treated with intravitreal anti-VEGF injections.
Cetin EN; Demirtaş Ö; Özbakış NC; Pekel G
Graefes Arch Clin Exp Ophthalmol; 2018 Oct; 256(10):1801-1806. PubMed ID: 29922890
[TBL] [Abstract][Full Text] [Related]
42. Multifocal electroretinography changes at the 1-year follow-up in a cohort of diabetic macular edema patients treated with ranibizumab.
Baget-Bernaldiz M; Romero-Aroca P; Bautista-Perez A; Mercado J
Doc Ophthalmol; 2017 Oct; 135(2):85-96. PubMed ID: 28779336
[TBL] [Abstract][Full Text] [Related]
43. Distribution of intraretinal exudates in diabetic macular edema during anti-vascular endothelial growth factor therapy observed by spectral domain optical coherence tomography and fundus photography.
Pemp B; Deák G; Prager S; Mitsch C; Lammer J; Schmidinger G; Scholda C; Schmidt-Erfurth U; Bolz M;
Retina; 2014 Dec; 34(12):2407-15. PubMed ID: 25062440
[TBL] [Abstract][Full Text] [Related]
44. Dril Influences Short-term Visual Outcome after Intravitreal Corticosteroid Injection for Refractory Diabetic Macular Edema.
Luís ME; Sampaio F; Costa J; Cabral D; Teixeira C; Ferreira JT
Curr Eye Res; 2021 Sep; 46(9):1378-1386. PubMed ID: 33463388
[No Abstract] [Full Text] [Related]
45. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.
Arevalo JF; Fromow-Guerra J; Quiroz-Mercado H; Sanchez JG; Wu L; Maia M; Berrocal MH; Solis-Vivanco A; Farah ME;
Ophthalmology; 2007 Apr; 114(4):743-50. PubMed ID: 17398322
[TBL] [Abstract][Full Text] [Related]
46. Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study).
Ehrlich R; Pokroy R; Segal O; Goldstein M; Pollack A; Hanhart J; Barak Y; Kehat R; Shulman S; Vidne O; Abu Ahmad W; Chowers I
Eur J Ophthalmol; 2019 Mar; 29(2):229-233. PubMed ID: 29916263
[TBL] [Abstract][Full Text] [Related]
47. Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema with Serous Retinal Detachment.
Kaya M; Karahan E; Ozturk T; Kocak N; Kaynak S
Korean J Ophthalmol; 2018 Aug; 32(4):296-302. PubMed ID: 30091308
[TBL] [Abstract][Full Text] [Related]
48. Behavior of hyperreflective spots noted on optical coherence tomography following intravitreal therapy in diabetic macular edema: A systematic review and meta-analysis.
Ganne P; Krishnappa NC; Karthikeyan SK; Raman R
Indian J Ophthalmol; 2021 Nov; 69(11):3208-3217. PubMed ID: 34708775
[TBL] [Abstract][Full Text] [Related]
49. Optical coherence tomographic evaluation of foveal hard exudates in patients with diabetic maculopathy accompanying macular detachment.
Ota M; Nishijima K; Sakamoto A; Murakami T; Takayama K; Horii T; Yoshimura N
Ophthalmology; 2010 Oct; 117(10):1996-2002. PubMed ID: 20723993
[TBL] [Abstract][Full Text] [Related]
50. Predictive capacity of baseline hyperreflective dots on the intravitreal dexamethasone implant (Ozurdex®) outcomes in diabetic macular edema: a multicenter study.
Fonollosa A; Zarranz-Ventura J; Valverde A; Becerra E; Bernal-Morales C; Pastor-Idoate S; Zapata MA
Graefes Arch Clin Exp Ophthalmol; 2019 Nov; 257(11):2381-2390. PubMed ID: 31451909
[TBL] [Abstract][Full Text] [Related]
51. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.
Maturi RK; Glassman AR; Liu D; Beck RW; Bhavsar AR; Bressler NM; Jampol LM; Melia M; Punjabi OS; Salehi-Had H; Sun JK;
JAMA Ophthalmol; 2018 Jan; 136(1):29-38. PubMed ID: 29127949
[TBL] [Abstract][Full Text] [Related]
52. Outcomes of Patients With Active Diabetic Macular Edema at the Time of Cataract Surgery Managed With Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
Starr MR; Mahr MA; Smith WM; Iezzi R; Barkmeier AJ; Bakri SJ
Am J Ophthalmol; 2021 Sep; 229():194-199. PubMed ID: 33852907
[TBL] [Abstract][Full Text] [Related]
53. The incidence and risk factors for the development of vitreomacular interface abnormality in diabetic macular edema treated with intravitreal injection of anti-VEGF.
Chang CK; Cheng CK; Peng CH
Eye (Lond); 2017 May; 31(5):762-770. PubMed ID: 28106889
[TBL] [Abstract][Full Text] [Related]
54. Intravitreal ranibizumab alone or in combination with panretinal photocoagulation for the treatment of proliferative diabetic retinopathy with coexistent macular edema: long-term outcomes of a prospective study.
Chatziralli I; Dimitriou E; Theodossiadis G; Kazantzis D; Theodossiadis P
Acta Diabetol; 2020 Oct; 57(10):1219-1225. PubMed ID: 32472172
[TBL] [Abstract][Full Text] [Related]
55. Baseline predictors for visual acuity loss during observation in diabetic macular oedema with good baseline visual acuity.
Busch C; Okada M; Zur D; Fraser-Bell S; Rodríguez-Valdés PJ; Cebeci Z; Lupidi M; Fung AT; Gabrielle PH; Giancipoli E; Chaikitmongkol V; Laíns I; Santos AR; Kunavisarut P; Sala-Puigdollers A; Chhablani J; Ozimek M; Hilely A; Degenhardt V; Loewenstein A; Iglicki M; Rehak M;
Acta Ophthalmol; 2020 Nov; 98(7):e801-e806. PubMed ID: 32115886
[TBL] [Abstract][Full Text] [Related]
56. IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA.
Wirth MA; Wons J; Freiberg FJ; Becker MD; Michels S
Retina; 2018 Sep; 38(9):1824-1829. PubMed ID: 28767550
[TBL] [Abstract][Full Text] [Related]
57. Comparison of clinical outcomes of different components of diabetic macular edema on optical coherence tomography.
Hu Y; Wu Q; Liu B; Cao D; Dong X; Zhang L; Li T; Yang X; Yu H
Graefes Arch Clin Exp Ophthalmol; 2019 Dec; 257(12):2613-2621. PubMed ID: 31529324
[TBL] [Abstract][Full Text] [Related]
58. Intravitreal injection of methotrexate in persistent diabetic macular edema: a 6-month follow-up study.
Falavarjani KG; Golabi S; Modarres M
Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2159-2164. PubMed ID: 27145784
[TBL] [Abstract][Full Text] [Related]
59. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.
Vujosevic S; Torresin T; Bini S; Convento E; Pilotto E; Parrozzani R; Midena E
Acta Ophthalmol; 2017 Aug; 95(5):464-471. PubMed ID: 27775223
[TBL] [Abstract][Full Text] [Related]
60. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]